<SEC-DOCUMENT>0001125345-24-000091.txt : 20240509
<SEC-HEADER>0001125345-24-000091.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509160621
ACCESSION NUMBER:		0001125345-24-000091
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		24930488

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mgnx-20240509.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c90b45e1-c5c0-4f17-ac4d-ec077cd3d408,g:dcdbda0c-39bc-40c7-b5b0-55cd8a3c4a98,d:171f1a9e4a0340e58853199f2bcf9bb3-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20240509</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20240509.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i171f1a9e4a0340e58853199f2bcf9bb3_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May&#160;9, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Exact Name of Registrant as Specified in Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:33.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36112</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">06-1591613</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Identification No.)</span></div></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.426%"><tr><td style="width:1.0%"/><td style="width:23.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.655%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.692%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt;padding-right:24.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">9704 Medical Center Drive</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Rockville,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">20850</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">301</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.051%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">MGNX</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-19">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i171f1a9e4a0340e58853199f2bcf9bb3_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9, 2024,  MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March&#160;31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:15.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.332%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d) Exhibits.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:15.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit99-1earningspressre.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit99-1earningspressre.htm">Press Release dated M</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit99-1earningspressre.htm">ay 9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit99-1earningspressre.htm">, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.841%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 9, 2024</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and General Counsel</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1earningspressre.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i35e9e57bdb9c48de882b8755daa8dc19_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div></div><div><img alt="macrogenics20logo_jpgormat.jpg" src="macrogenics20logo_jpgormat.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:165px"></div><div style="padding-right:-6.75pt;text-align:center"><font><br></font></div><div style="padding-right:-6.75pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data</font></div><div style="padding-right:-6.75pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#6d6d6d;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Presentation of interim TAMARACK Phase 2 study data&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">updated safety and preliminary efficacy</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> of vobra duo in mCRPC patients</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.03pt">Conference call scheduled for today at&#8239;4&#58;30 p.m. ET</font></div><div style="margin-bottom:6pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ROCKVILLE, M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D., May&#160;9, 2024 </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(GLOBE NEWSWIRE)</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8212; MacroGenics, Inc. (NASDAQ&#58; MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March&#160;31, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;We are very encouraged by the interim updated safety and preliminary efficacy data from the TAMARACK study of vobra duo in metastatic castration-resistant prostate cancer,&#34; said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. &#8220;We believe this interim data set helps validate our previously stated hypothesis that improved tolerability coupled with compelling biological activity could be achieved through dose reductions and a longer dosing interval. We believe vobra duo&#8217;s biological activity shown to date aligns well with the parameters we outlined at the outset of the study. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Based on our evaluation of the interim data to date, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">we have initiated planning activities for a potential Phase 3 study that could commence next year. We anticipate sharing final </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">safety, efficacy and durability data, including radiographic progression-free survival data, which is the primary endpoint of the study, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the second half of 2024. Furthermore, having preliminarily identified suitable vobra duo doses in mCRPC in the TAMARACK study, we have greater confidence in the molecule&#8217;s potential to help patients with a broad range of B7-H3-expressing cancers.&#8221;</font><font style="background-color:#ffffff;color:#6d6d6d;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;The interim safety and anti-tumor activity observed to date in the TAMARACK study look very promising for patients with metastatic castration-resistant prostate cancer,&#8221; said Johann DeBono, Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust. &#8220;With the limited treatment options currently available to these patients, this novel ADC molecule could potentially become the first therapy targeting B7-H3 in patients with prostate cancer and would represent an important new treatment for this population.&#8221;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Updates on Proprietary Investigational Programs </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Recent progress and anticipated events related to MacroGenics&#8217; investigational product candidates are highlighted below.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">B7-H3-Directed Therapies</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Vobramitamab duocarmazine (vobra duo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) is an antibody-drug conjugate (ADC) that targets B7-H3, an antigen with broad expression across multiple solid tumors and a member of the B7 family of molecules involved in immune regulation.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">MacroGenics completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023. TAMARACK is being conducted in patients with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with one prior androgen receptor axis-targeted therapy (ARAT). Participants may have received up to one prior taxane-containing regimen, but no other chemotherapy agents. The TAMARACK study is designed to evaluate vobra duo at two different doses&#58; 2.0 mg&#47;kg or 2.7 mg&#47;kg every four weeks (q4W).</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">A new presentation of TAMARACK interim data, consisting of updated safety and preliminary efficacy data, all based on a data cut-off date of April 12, 2024, is available under &#34;Events &#38; Presentations&#34; in the Investor Relations section of MacroGenics&#8217; website or directly via </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">this link</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Below is a high-level summary of this interim data, which is subject to further updates&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.698%"><tr><td style="width:1.0%"></td><td style="width:45.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vobra Duo</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;2.0 mg&#47;kg q4W</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vobra Duo</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">2.7 mg&#47;kg q4W</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Patients Enrolled</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">n&#61;91</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">n&#61;90</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PSA Reduction Summary&#58;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">PSA Evaluable Patients</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">n&#61;82</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">n&#61;71</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Any PSA Reduction &#8805;50%</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">41 (50.0%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">36 (50.7%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Confirmed PSA Reduction &#8805;50%</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">36 (43.9%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">26 (36.6%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Tumor Response Summary&#58;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">RECIST Evaluable Patients with Measurable Disease at Baseline</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">n&#61;45</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">n&#61;32</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Disease Control Rate (CR+PR+SD)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">41 (91.1%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">28 (87.5%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Overall Response Rate (CR+PR, confirmed only)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8 (17.8%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8 (25.0%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Overall Response Rate (CR+PR, including unconfirmed)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">11 (24.4%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">14 (43.8%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Safety Summary&#58;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Safety Population</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">n&#61;90</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">n&#61;86</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Treatment-Emergent Adverse Events All Grade</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">89 (98.9%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">86 (100.0%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Treatment- Emergent Adverse Events Grade &#8805;3</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">49 (54.4%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">44 (51.2%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">TEAE Leading to Study Drug Discontinuation</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10 (11.1%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">13 (15.1%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">TEAE Leading to Study Drug Dose Reduction</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">39 (43.3%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">44 (51.2%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">TEAE Leading to Study Drug Dose Interruption</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">38 (42.2%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">48 (55.8%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Five Most Common TEAE All Grade</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Asthenia (46.7%) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Nausea (35.6%) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Oedema peripheral (32.2%) Decreased appetite (28.9%) Fatigue (25.6%)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Asthenia (58.1%) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Decreased appetite (37.2%) Oedema peripheral (36.0%) Nausea (30.2%)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pleural effusion (29.1%)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Pleural Effusions</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 1&#61;8.9%</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 2&#61;8.9% </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">No Grade &#8805; 3 event</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 1&#61;14.0% </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 2&#61;14.0% </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 3&#61;1.2%</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Palmar-plantar Erythrodysaesthesia Syndrome</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 1&#61;11.1% </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 2&#61;4.4% </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">No Grade &#8805; 3 event</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 1&#61;12.8% </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 2&#61;9.3% </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grade 3&#61;1.2%</font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#6d6d6d;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The median number of cycles of vobra duo administered was five (range of 1-10).</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">A total of five events with fatal outcome occurred as follows&#58; one Grade 5 event in the 2.0 mg&#47;kg dosing cohort&#58; acute myocardial infarction (considered unrelated to study drug by the investigator)&#59; three Grade 5 events in the 2.7 mg&#47;kg dosing cohort&#58; one cardiac arrest (considered unrelated to study drug by the investigator) and two events of pneumonitis. In addition, a patient in the 2.7 mg&#47;kg dosing cohort had a Grade 3 pleural effusion that is recorded as having a fatal outcome. The latter three deaths are being investigated, as follow-up is incomplete on this ongoing trial.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Additional data is provided in the presentation on the Company&#8217;s website and as filed with the Securities and Exchange Commission.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Based on a current evaluation of this interim data, the Company is undertaking the initial steps necessary to prepare for the potential initiation of a Phase 3 study in mCRPC in 2025. The final decision to pursue such a Phase 3 study will be based on an analysis of the final data set, including rPFS, when available.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company intends to share final safety, efficacy, and durability data, including the primary endpoint of radiographic progression-free survival, from the TAMARACK trial in the second half of 2024.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">MacroGenics plans to expand the TAMARACK study of vobra duo by enrolling patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN) and anal cancer. The Company expects to initiate dosing in these additional cohorts in mid-2024.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">MacroGenics continues to enroll a Phase 1&#47;2 dose escalation study of vobra duo in combination with lorigerlimab in patients with various advanced solid tumors. The Company anticipates commencing a dose expansion study of this combination in mCRPC and at least one additional indication in 2024.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">MGC026</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is a clinical B7-H3-targeting ADC that is site-specifically conjugated to exatecan, a topoisomerase I inhibitor payload developed by Synaffix (a Lonza company). With distinct mechanisms of action, vobra duo and MGC026 may address different cancers, tumor stages, or be used in combination with alternate agents &#8212; or potentially with one another &#8212; to enhance their clinical utility. A Phase 1 dose escalation study of MGC026 in patients with advanced solid tumors is ongoing.</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MGC026 preclinical data was presented recently at the American Association for Cancer Research (AACR) Annual Meeting. In preclinical studies, MGC026 was shown to have greater potency than B7-H3-directed antibodies conjugated to deruxtecan, or DXd, a topoisomerase-based payload utilized in other ADCs. In addition, the MGC026 payload has been shown to be less susceptible to multi-drug resistance (MDR) mechanisms than DXd and SN-38. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Enoblituzumab </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is an Fc-optimized monoclonal antibody that targets B7-H3. The HEAT study, an investigator-sponsored, randomized Phase 2 clinical trial being conducted by MacroGenics&#8217; academic collaborators, is ongoing. This study is being conducted to evaluate the activity of neoadjuvant enoblituzumab given prior to radical prostatectomy in up to 219 men with high-risk localized prostate cancer.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lorigerlimab</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Lorigerlimab </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is a bispecific, tetravalent PD-1 &#215; CTLA-4 DART&#174; molecule. In addition to the ongoing study of lorigerlimab in combination with vobra duo mentioned above, MacroGenics is enrolling LORIKEET, a randomized Phase 2 study of lorigerlimab in combination with docetaxel vs. docetaxel alone in second-line, chemotherapy-na&#239;ve mCRPC patients. A total of 150 patients are planned to be treated in the 2&#58;1 randomized study. The current trial design includes a primary study endpoint of radiographic progression-free survival (rPFS). The Company anticipates completing enrollment of the study in 2024 and providing a clinical update in the first half of 2025.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Emerging ADC Pipeline</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">MGC028 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is a preclinical ADC incorporating an ADAM9-targeting antibody and represents the second MacroGenics ADC molecule that incorporates Synaffix&#8217;s novel site-specific linker and topoisomerase I inhibitor-based cytotoxic payload. ADAM9 (a disintegrin and metalloprotease domain 9) is a member of the ADAM family of multifunctional type 1 transmembrane proteins that play a role in tumorigenesis and cancer progression and is overexpressed in multiple cancers, making it an attractive target for cancer treatment. The Company currently anticipates submitting an investigational new drug (IND) application for MGC028 by the end of 2024.   </font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MGC028 preclinical data was presented recently at the AACR Annual Meeting. In preclinical studies, MGC028 demonstrated specific antitumor activity in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> models representing gastric, lung, pancreatic, colorectal cancer, SCCHN and cholangiocarcinoma. In addition, in a non-human primate study, MGC028 was well tolerated at high dose levels, with mild, reversible side effects and no ocular toxicity, which is often a concern with tubulin-inhibitor-based ADCs. These promising preclinical results support the continued investigation of MGC028 as a therapeutic option for treating ADAM9-expressing solid cancers.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Partnered Program</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">MGD024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is a next-generation, humanized CD123 &#215; CD3 DART molecule designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing. MacroGenics continues to enroll patients in a Phase 1 dose-escalation study of MGD024 in patients with CD123-positive neoplasms, including acute myeloid leukemia and myelodysplastic syndromes. Under an October 2022 exclusive option and collaboration agreement, Gilead Sciences, Inc. has the option to license MGD024 at predefined decision points during the Phase 1 study.</font></div><div><font><br></font></div><div id="i35e9e57bdb9c48de882b8755daa8dc19_4"></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Quarter 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Financial Results</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Cash Position</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Cash, cash equivalents and marketable securities balance as of March&#160;31, 2024, was $184.2 million, compared to $229.8 million as of December&#160;31, 2023. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12.03pt">Revenue</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Total revenue was $9.1 million for the quarter ended March&#160;31, 2024, compared to total revenue of $24.5 million for the quarter ended  March&#160;31, 2023. The decrease was primarily due to a decrease in revenue from collaborative and other agreements, including a $15.0 million milestone received from Incyte in the quarter ended March 31, 2023. </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12.03pt">R&#38;D Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Research and development expenses were $46.0 million for the quarter ended March&#160;31, 2024, compared to $45.9 million for the quarter ended March&#160;31, 2023.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12.03pt">SG&#38;A Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Selling, general and administrative expenses were $14.7 million for the quarter ended March&#160;31, 2024, compared to $13.5 million for the quarter ended March&#160;31, 2023. The increase was primarily related to increased stock-based compensation expense and other professional fees.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12.03pt">Net Loss</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Net loss was $52.2 million for the quarter ended March&#160;31, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> compared to net loss of $38.0 million for the quarter ended March&#160;31, 2023.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12.03pt">Shares Outstanding</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Shares of common stock outstanding as of March&#160;31, 2024 were 62,560,502.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12.03pt">Cash Runway Guidance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $184.2 million as of March&#160;31, 2024, in addition to projected and anticipated future payments from partners and product revenues should extend its cash runway into 2026. The Company&#8217;s expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial, the Phase 2 LORIKEET study as well as MacroGenics&#8217; other ongoing clinical and preclinical studies. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conference Call Information</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To participate via telephone, please register in advance at this</font><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> link</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The listen-only webcast of the conference call can be accessed under &#34;Events &#38; Presentations&#34; in the Investor Relations section of </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MacroGenics&#8217;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> website at </font><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">http&#58;&#47;&#47;ir.macrogenics.com&#47;events.cfm</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MacroGenics&#8217;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> website for 30 days following the call. </font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELECTED CONSOLIDATED BALANCE SHEET DATA</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:138%">(Amounts in thousands)</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,237&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,805&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,285&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,019&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,894&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,154&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,613&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:174%">(Amounts in thousands, except share and per share data)</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.391%"><tr><td style="width:1.0%"></td><td style="width:64.095%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.370%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,686&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,861&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,104&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,496&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing services</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,029&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,872&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,709&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,527&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,854&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,922&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,750)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,426)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,693&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,190)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,009)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,219)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,996)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.84)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.61)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,290,538</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,809,817</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About&#8239;MacroGenics, Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, MARGENZA and DART are trademarks or registered trademarks of MacroGenics, Inc.   </font></div><div><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cautionary Note on Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any statements in this press release about future expectations, plans and prospects for MacroGenics (&#8220;Company&#8221;), including statements about the Company&#8217;s strategy, future operations, clinical development of the Company&#8217;s therapeutic candidates, including initiation and enrollment in clinical trials, expected timing of results from clinical trials, discussions with regulatory agencies, commercial prospects of or product revenues from MARGENZA and the Company&#8217;s product candidates, if approved, manufacturing services revenue, milestone or opt-in payments from the Company&#8217;s collaborators, the Company&#8217;s anticipated milestones and future expectations and plans and prospects for the Company, as well as future global net sales of TZIELD and the Company&#8217;s ability to achieve the milestone payments set forth under the terms of the agreement with DRI (or its successors or assigns with respect to such agreement), and other statements containing the words &#8220;subject to&#8221;, &#34;believe&#34;, &#8220;anticipate&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;potential,&#8221; &#8220;project&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;can&#8221;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate&#8217;s revenue, expenses and costs may not be as expected, risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate&#8217;s market acceptance, competition, reimbursement and regulatory actions&#59; future data updates, especially with respect to vobramitamab duocarmazine&#59; our ability to provide manufacturing services to our customers&#59; the uncertainties inherent in the initiation and enrollment of future clinical trials&#59; the availability of financing to fund the internal development of our product candidates&#59; expectations of expanding ongoing clinical trials&#59; availability and timing of data from ongoing clinical trials&#59; expectations for the timing and steps required in the regulatory review process&#59; expectations for regulatory approvals&#59; expectations of future milestone payments&#59; the impact of competitive products&#59; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates&#59; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises such as the novel coronavirus (referred to as COVID-19 pandemic)&#59; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">### </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTACTS&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jim Karrels, Senior Vice President, CFO </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1-301-251-5172 </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">info&#64;macrogenics.com </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mgnx-20240509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c90b45e1-c5c0-4f17-ac4d-ec077cd3d408,g:dcdbda0c-39bc-40c7-b5b0-55cd8a3c4a98-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20240509" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20240509">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20240509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20240509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://macrogenics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mgnx-20240509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c90b45e1-c5c0-4f17-ac4d-ec077cd3d408,g:dcdbda0c-39bc-40c7-b5b0-55cd8a3c4a98-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_df556834-7290-4cca-8d93-1b5fcb611817_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0ceb61f2-e821-4130-af69-d73be7b38d5e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_89f6878c-8147-461b-80ab-39b048eeebbd_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d94c82a6-16aa-4db9-9bcb-cd76bd909313_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e646ae91-9c1f-48c7-9beb-2af6ce5e70cf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8a9c307d-398c-44f6-bc15-7135cbb6d478_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9e3cd142-3a5f-4084-bde5-4b05a9b07b6d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b1eeb64c-4bfd-497f-bbc1-563ba89202aa_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6d878853-21d1-45bb-aac1-e1b9aeb0920a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fd89f22f-e8fb-4c66-b84b-d4d53d6635d6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_824b5d5b-9a0d-4b89-b0b8-14285367e14e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_196d904a-ce44-44cd-b8aa-a1408ca0fda5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ef164f5c-1b72-4d52-96dc-2133a7691e51_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7f4e36da-5501-4e67-bdab-4b2eb2a5f2c8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e052c2a7-433b-4dab-9133-3d5345b21f31_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7c852792-5207-479f-8da6-7a98dfd4dcb4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ee051c04-b6b7-40bc-83e6-e26d5c168515_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_adf99c22-9ed2-4fd3-8657-5dc712b2873e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9124cdc3-ed9a-4e51-9636-7ed0e4e5df8b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d7773b87-f6c6-4569-9f74-0bb647d48818_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_71aa7a19-b9c3-4df5-ad91-c4b69be1af41_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_30321bd0-73dd-4e77-8104-908059f32748_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mgnx-20240509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c90b45e1-c5c0-4f17-ac4d-ec077cd3d408,g:dcdbda0c-39bc-40c7-b5b0-55cd8a3c4a98-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20240509.xsd#Cover"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fa9bb779-31bf-4d72-89c7-42e00fab9340" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_DocumentType_fa9bb779-31bf-4d72-89c7-42e00fab9340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4c761bf1-c8ce-4d7a-9714-c64e0a602961" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_DocumentPeriodEndDate_4c761bf1-c8ce-4d7a-9714-c64e0a602961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_75328987-c4b2-41e3-bc52-004bd78d950d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityRegistrantName_75328987-c4b2-41e3-bc52-004bd78d950d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8f9d73a6-0add-4619-8a86-40ab0c627065" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8f9d73a6-0add-4619-8a86-40ab0c627065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_59735e15-91d6-4b6a-8ef9-ab714976bd16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityFileNumber_59735e15-91d6-4b6a-8ef9-ab714976bd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dba00136-29d9-4d52-8015-a6fa7bca37d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityTaxIdentificationNumber_dba00136-29d9-4d52-8015-a6fa7bca37d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c9dc305c-a7b3-4bfe-a721-62cbc69dae7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityAddressAddressLine1_c9dc305c-a7b3-4bfe-a721-62cbc69dae7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_93831386-427a-46f9-aaa7-ad47be999afe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityAddressCityOrTown_93831386-427a-46f9-aaa7-ad47be999afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4e000030-9dac-4a2a-82ad-d9b306f2af04" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityAddressStateOrProvince_4e000030-9dac-4a2a-82ad-d9b306f2af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4d9d217e-ada9-4a95-82e6-90ab4ceda362" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityAddressPostalZipCode_4d9d217e-ada9-4a95-82e6-90ab4ceda362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_05326dcf-32c3-42a4-9669-9f0d3ad8e4f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_CityAreaCode_05326dcf-32c3-42a4-9669-9f0d3ad8e4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_13f398ea-c4e0-4320-8f07-c81c4e0f23ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_LocalPhoneNumber_13f398ea-c4e0-4320-8f07-c81c4e0f23ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e390c7f7-f3ca-4201-9263-e7dff0d6fa6d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_Security12bTitle_e390c7f7-f3ca-4201-9263-e7dff0d6fa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b85f37d2-fa6e-4bf7-83d2-1976212d5628" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_TradingSymbol_b85f37d2-fa6e-4bf7-83d2-1976212d5628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_67da0f8b-6dcb-43b9-bd76-5541090e2b8b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_SecurityExchangeName_67da0f8b-6dcb-43b9-bd76-5541090e2b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_1500af16-1050-43f1-9430-4fad42a1c142" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_WrittenCommunications_1500af16-1050-43f1-9430-4fad42a1c142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_1613f274-b164-469d-8f0a-161e11433f92" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_SolicitingMaterial_1613f274-b164-469d-8f0a-161e11433f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a2a9ae2a-6704-49c0-b03d-94bac6bc6168" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_PreCommencementTenderOffer_a2a9ae2a-6704-49c0-b03d-94bac6bc6168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_336bccb2-71d8-4ef6-b2d2-e415a8a0249f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_336bccb2-71d8-4ef6-b2d2-e415a8a0249f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_01f70574-6d1d-4ed7-89ea-b7c095a47104" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityEmergingGrowthCompany_01f70574-6d1d-4ed7-89ea-b7c095a47104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4966ef1a-2aa1-4afb-83b0-6f311e0580db" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_EntityCentralIndexKey_4966ef1a-2aa1-4afb-83b0-6f311e0580db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_38145bfc-1e9a-45bb-9f85-7e03b1500624" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57ed1597-3657-4e6a-9fdc-c2465ecfd4c1" xlink:to="loc_dei_AmendmentFlag_38145bfc-1e9a-45bb-9f85-7e03b1500624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>macrogenics20logo_jpgormat.jpg
<TEXT>
begin 644 macrogenics20logo_jpgormat.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0""17AI9@  34T *@    @  8=I  0
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>;>/]?\ M<YTVT;]
MQ&W[UA_&P[?0?S^E=!XYU_\ LNS^S6KXO)AU!YC7U^OI7EJJTCA5!9V.  ,D
MFF@+>D:=-JE_':VX^9CRQZ*.Y->S:78PZ;8Q6MLN(XQC/<GN363X.T(:-I^9
M0#>3#,A_N^BBN@H; ****0!1110 4444 %%%% !1110 4444 %%%% !1110
M Y''-%5Y$:([XN5[K4L4JRKE?Q'I0 ^BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 4444 %%%% !1110 4444 %%1O<0I*L;RQK(WW5+ $_A4E !1110
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M$'D3D#[C<K0!O45GZ3<^8GE,?F7I[BM"@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 9^M0>9:[Q]Z/G\.]8$,IAF61>JG-=<RAU*MR",&N.N$,,SQMU
M4D4P.PBD$L:NOW6&13JRO#UQYENT1/,9X^AK5I %%%% !1110 4444 %%%%
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M<=L[!W!+,R]"2:TJ*SIX&A3K.O"-I-6T+EB:LZ?LI2NCC_B1_P >-G_UU/\
M*N KO_B1_P >-G_UU/\ *N KX;B'_?I>B_(^FRG_ ':/S_,[_P"'"@Z;=9 /
M[WO]!75S012H4EB1U/4,H(KD/A[<P0:?="::*,F7(#N!GBNFN-7T^WC+R7D
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MO%G4HQ4]5.#7PW$>"AAZL:E-64K_ 'H^ERC$RJTW";ORG0>!KYK36EA)_=7
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M\3M1W26^G1GA?WLGUZ ?S_,5PE4@-+PY9?VAK=G;X)5I 7_W1R?T%>U5Y_\
M#'3\R75^XX4>4A]^I_I7H%)@%%%%( HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \S\??\C"W_7-:M_#C_D)W7_7'_P!F%5/'W_(PM_US6K?PX_Y"
M=U_UQ_\ 9A7P=+_D=/\ Q/\ 4^HJ?\B[Y(]!HHHK[P^7"BBB@ HHHH ****
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MXG^I]14_Y%WR1Z#1117WA\N%%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1128&I;^!=*C(,K7$WLSX'Z 5K6GA[2;7F&P@SZNN\_KFBBD!J*JHH5 %4=
M!@"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_Q  ? 0 " @,! 0$! 0
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MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L3\Q:9S4ZA
MOQH/])4=P.C?1WP@JPNN%#/-!U?ZV@M+AO\ 28A\#G_=BC^([X$LDP*[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78JA;R]LM/@:ZO[N&QMDH'N+B18D%>E6<@8JA=,US1=:5GT?6++5D3[;V=
MQ'.!\S&S4Q5-,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKXU_YR#_,_Z[-+Y"T.X_T6U<'S'=1G:25=UM@1^RAH7_RJ#]DUG$*^
M4\DA<B,[*B*7=R%1%%22=@ !BK]!_P E?RS7R-H?Z1U2$?XGUI%>]J*FVA-&
M6W!\1U>G[6V_$'(2-I>VY%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%6B 0014'8@XJ\WUO33I]S5!_HT]6A/AXK]&%4GCE>"1)8F*21D,C#
MJ",5>FZ5J4>I6PD%%F3X9X_!O$>Q[8%33%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_,;\Q//>J>?/,-[J-U
M<R?HR.9UT;3B3Z<$ -$HO3DP%6/<^U +0*0Q32-7U/0=0MM5TB]EL-0LW#P7
M,1H01V/8@]"#L1L<5?HG^5OYE6'YAZ*)3PM=?T]536=.!Z,=A-'7JCTV_E.Q
M[$UD4EZC@5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O%?
MSI_,Q/(NA_4--F'^)]9C9;!1N;>+[+W##M3HE>K>/$Y*(M7YZN[R.\DCF220
MEG=C4L3N22>I.30MQ5]4?\X^?EA^D+B/SYKMM6RLY/\ G7+:0;2SH:&X(/[,
M9%%_RM_V=XR*7V=D%=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL506H64=_:R6[[%A6-_Y6'0XJ\IGBDMY9(9EX21,5=3XC"J)TW49-.N
MDG2I3[,T?\RGJ/Z8J]5@FCN(8YX6#Q2J&1AX' JKBKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\O?/WDW4/(WF6
M_P!%O(7%N)&DTJZ(^&>V9CZ;J?&FS#L:C+0;0PO%4_\ +/F75O*.M6>NZ+<>
MA>VC=#4QRH?M1R+4<E8=1](H0#B0K](_(?GG2//VA0ZSIC>E,O[O4M.9@9+:
M;NC4Z@]5:FX\#4"LBDLTP*[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%6->;_-6F>3- OO,&JO\ N+1:0P @//,W]W$E>['[A4G880+5^9OFCS+J
M?F[7;_7]6E]2[OY.7 ?8BC&R1(.RHNP^\[URP!"08J]._*K\N[G\PO,26KAX
M=$T[C-K=XNU(R?AB0_SR4('@*GM@)I7Z06EI;6%K;V5E EM:6D:PVUO&.*)&
M@XJJCL !E:41BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL58=YITWG&-1B7XX@%N0.Z]F^CI_M858"6Q5E?E?5_0F_1\[4@G/[AC^
MRY[?)OUXJ]$P*[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78JP'\Q/(&E_F#H,FF7H$%_!RDT?4P*O;S4VKW*-L'7N/
M< @@TK\X/,'E_5?*^KWNB:S;&UO[%RDBFO%A^RZ$@<E8;@]QEB$FQ5FWD+SS
MJWD'78=7TUO4@>D>IZ<Q(CN8:[JW@PZJW8^U04BU?I%Y9\RZ3YMT:SUW1;@3
MV5XM>)ISB<?:BD4$\64]1_#*DI]BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL54YIHK>*6>>188($:2:9R%54459F)V  %3BK\[?SB_,F7S]KYBLI67R
MUI#-'I,.X]5NCW#CQ>GPUZ+[ELL I#Q_"J;:%HFI>8]7L-$TFW-SJ&HRB*WB
M'3Q+,>RJ 68]@*XJ_2[R)Y+TWR)Y=M-"T\!Y%_>ZC>THUQ<,!SD/MM11V  R
MLFTLRP*[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8JM=%D1D=0R."KJ>A!V(.*O(-7T]M-OI;<U,9^.!SW0]/NZ852OE0U&Q'0XJ
M]6\O:J-3LP)&K=VU$G'=O!_I_7@5/\5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>1_FS^5]G^86D>I;+':^9M.0
MG2KXT D&Y-O*:5X,>A_9._2H)!I7YWWUC>:9>7.GZA;26=[9R-%=6THXNCJ:
M$$98A"XJ]2_*S\S+_P#+S60[F2Z\O7[*NL::#7;8>M$"0!(H_P""&Q[$ BU?
MHMIFI6.L6%IJFF727EA?1B6UN8S565OU$="#N#L<K2CL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5?)'_ #D)^9_ 2^0="N/B< ^9;N,] =UM01X[%_H7
M^89.(5\@9)#NNPW)Q5][_D7^6(\H:1_B+6(*>9-;B'&)Q1K2U:C+%0]'?9G\
M-E[&L)&TO?\ (J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78JQSS-IOUZP:6-:W%G61*=2O[2_=OBKRDGPR2IAI&I/I=]%<
MK4Q_9N$'[2'K]W48E%O9HY$EC26-@\<BAD<=""*@Y%*_%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7S_P#G7^4B
M><K-O,6@P*OFFPC_ 'L*T'UZ%1LC?\6*!\![_9/[/&432O@MT>-WCD0QR1DJ
MZ,*%2-B"#T(R:%N*O=?R9_-F7R/?C1M:E>7RIJ,E93NQLI6V]9 -RI_;4?ZP
MW%&!%J^_8I8IXHYX)%FAF4/#,A#*ZL*JRL-B"-P1E:53%78J[%78J[%78J[%
M78J[%78J[%78J[%7DOYN_F3!^7^@'ZJZ2>8]55HM'MC0\.SW#C^5*[5ZM0=*
MT(%J_.>:::YFEN+B5Y[BX=I)YY"6=W<U9F8[DDFI)RQ"GBKZ6_('\L/T]?IY
MSUNVY:+I<O\ N)MY!M<W2'[=#U2(CZ6V_9(R,BK[@R"78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7C_F+3OT;J,B
MHO&WG_>V_@ >J_0?PPH*0%L*O1?)NK>K$^ES-\<(+VI/=*_$OT'?_:P%+.L"
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5\J?GM^4/U]+OSQY9MO\ 3HE,OF#38Q_?(HJUR@_G4#XP/M#?[5>4
MHE7QIDT.Q5]/?D7^;WZ%EMO)GF6Y_P!P]P_#1=1D/^\LCG:%S_OMB=B?LG_)
M/PQD%?;&02[%78J[%78J[%78J[%78J[%78J[%4C\R>8M,\JZ+?Z]J\WHV5A&
M7<#[4C'9(T!ZLYH ,5?F=YR\VZGYV\P7NOZH])+AN-M; U2"!2?3B3V4?>:G
MOEH%(8MBKT'\M?(5[^8/F2#2H><&FV])M:U!1_<P ] 3MS<_"H\=^@. FE?I
M/INFV.CV%GI>FVR6EA81+#:VR=$1!0#Q/N3N>IRM*.Q5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5CGF?3?K^F2.
MBUN+.LL7B0!\:_2/Q&(5X\6R2JUG>2V-U!=PFDD#A@/$=P?8C;%7NUI=17MM
M!=P'E%.@=#\^Q]QTR*HC%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J^*/ST_*(Z--<^<_+-K_ +B+AS)K>G1#
M:UD8[S(!_NMB=P/LG_)/PSB5?,&20[%7V7^1/YO?7DM?(_F>Z_TV,"+R]J4I
M_OD  6V<_P X'V"?M#X?M4Y0D$OJO(J[%78J[%78J[%78J[%78J[%6F8*"S$
M*JBK,=@ .YQ5^?7YV?F:?/&M?HO2IB?+&BR,+,J=KJ<?"UP?;J$]M_VJ"R(I
M#P_"J/TO3+[6M1LM)TRW:ZO]0E6&U@7JSL:#Y =23T&*OTI_+CR)8_E_Y;M]
M(M^,U_-2?6+\#>:X( -#UXKT4>&_4G*R;2S[ KL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKQ'S#I_Z+U2>!
M5I#)^]M_#@W;Z#49(*D).*'HOD75*^OI,K=*S6M?^'4?K^_ 5#T? EV*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*J<L44\4D$\:S0S*4FA<!E=6%&5E.Q!&Q!Q5\!_G-^4TOD>_;6M%B:7RIJ,G
M[L"K&RE;_=3G^0G[#'_5.X!:P&T/"<*KD=XW22-S')&0R.IH5(W!!'0C%7WG
M^2GYMIYQLX_+FO3A/--C'^ZG8@?7XD&[K_Q8H'QCO]H=Z0D*2^@<BKL5=BKL
M5=BKL5=BKL5=BKY:_P"<@OS/_1UK)Y%T*YI?WJ#_ !!<QG>&!Q46X(Z-(-V_
MR=OVMI1"OB[)H=BK[E_(/\L/\.Z<OG#6[;CKFK1?[C+>0?%:VKC[1!Z/*-SW
M"T&U6&0D4OI'(J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%6%>=M/^L:<E\BUEL6^.G>-]C]QH?OPA!>2
M$UPH5[*^DL+RVO(?[RW<.!TJ!U'R(VQ2^@[:XCNK>&YA;E%.BR1GV85&12K8
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%4#J>FV.L6%WI>IVJ7EA?1F*ZMI!565OU$=01N#N,5?G5^:GY9WWY
M>:R40277E[4&9M'U$BNW4PRD  2+^(W'<"P&T/+,*HJQOKS3+RVU#3[F2SO;
M.19;6YB/%T=34$'%7Z(?E-^:%G^86D>E=&.V\S:<@&J6*T42#H)X5J24/<?L
MG;I0FLBDO7,"NQ5V*NQ5V*NQ5V*O,_S3_,*U_+WRY)>J4EUN_P"4&A63;\Y:
M#E(PZ\(P:GQ-%VKA M7YO7M[=:C>75_?3O=7M[*\UU<R&K/(YY,Q/B2<L0AL
M5?0?Y$_EC_BS5?\ $NLV_+R[HLH]&%Q\-W=+1@E#U1-BWCLO<TC(J^\\@EV*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ52GACN(9;>5>44R,DB^(84.*OGF_MI+*[N;.7[=M(R$^-#L?
MI&^20@"V%+UKR#JGUBRGTV1JR63<X >IC<[CZ&_7D2KT# KL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BJ0^9
M?+>D^;=&O-"UJV%Q97BD5VYQ.!\,L;$'BZG<'[]JC%7YN^?O(NK>0->FTC4E
M]6W>LFEZBHI'<P5H&'@PZ,O8^U";0;0PG%4Y\OZ_JOEC5[/6]&NFM;^R</&X
MKQ8?M(X_:5AL1W&*OT?_ "[\_P"E_F#H,>IV1$%_!QCUC3":O;S4WIW*-N4;
MN/<$"LBDL^P*[%78J[%78JE6N:UIWEW2;_6]6N!;:?IT1EN)3UH.BJ.[,:!1
MW)IBK\TO/OG74?/GF.[UR^)CA;]UIEC6JV]NI/",>^]6/<DY:!2&%XJS7R#Y
M)U'S[YBM=$L08H#^]U.^I5;>W4CFY\2>BCN2.U3B32OTMT71M.\OZ58Z-I-N
M+73]/B$5M"/ =2Q[ECN3W.^5)33%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J\B_,"P]"_M]01?
M@O$X2G_BR/;?YJ1]V2"O/2<4)WY;U/\ 16LV=PS4A=O1N?#TY-B3\C0_1BKZ
M$R*78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78JPOSWY'TGS]H,^C:FOI2BLFG:BJ@R6TP&SKTJ#T9:[CWH
M00:5^;GF?RSJWE'6KS0M:M_0O+1MF&Z2QMNDD;=U8=/N-"",L!0D&*LM\E><
M]7\BZ[;:YI+U9/W=[9L2([F D%HGIXTJ#V-#B1:OTD\I>:](\Z:'::[HTWJ6
MUP.,T+;202K]N*0=F7\1N-B,K(I+)<"NQ5V*NQ5\%_GK^9_^+=5/ES1;GGY<
MT:4^K-&?AN[I:@O4=43<+X[MX9.(0^?<DJ)LK*ZU&\M;"Q@>ZO;V5(;6VC%6
M>1SQ50/$DXJ_2+\K?R]M/R]\N165$EUJ_"3Z[>KOSEIM&I_DCJ0OCNVU<K)M
M+TO KL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BK%_.%A]?T*[XBLMI2YB_YY_:_P"%)PA7@A.2
M8J3-X8I?0WE74OTIH=E.S<IHE]"X/?G'M4_,4/TY$I9%@5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O+
M_P TORUL/S#T4Q?!:Z]8*S:-J1'1CN8I*=4>GT'<=P2#2OSHU33+_1=0O-*U
M2V>SU"PE:&ZMGZJZ_*H([@C8C<98A 8J](_+/\QM2_+O7!>0AKK2+TK'K.F5
MH)8Q6CK78.E25/S'0X"+5^C>C:QIVOZ99:QI-TMYIU_&);:X6HJ#L00=P0=B
M#N#ME:4SQ5V*OFS\_?S._P /Z>_DW1+CCK>K0UU.YC.]K:O^R".CRC;V7?NI
MR40KX<R:'8J^TO\ G'W\L?T9:Q>>M<MZ:A?Q'] 6SC>&!Q0SD'HT@V7P7_6V
MA(I?4F15V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*K719$9'4,C@JZGH0=B,5?,NJ6K:?J%
M[9/UM9GC!\0#\)^D;Y)"6DX5>F?EIJ7"ZOM+=OAG07$ /\R?"P'N00?HR)4/
M8L"78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%7AOYR_E1#YZTXZOI$:1>:M-B/H'8"\B4$^@YV :OV&
M/?8[&HD#2OS_ )H9K::6WN(G@N+=VCG@D!5T=#1E93N""*$')H4\5>T?D]^:
MEQY!U3ZAJ+O-Y6U.0?7H15C;2&@^L1@5.P^T!U'N!@(M7Z#VMU;WMM;WEI.E
MS:74:S6UQ&P9)(W 965AL00:@Y6E@_YD>?+'\O\ RY<:K/QFU">L.C6!.\TY
M&U0-^"=6/AMU(P@6K\UM3U.^UG4+S5=3N&N[^_E::ZN'ZL[&I]@.P V V&6(
M0.*O<?R2_+(^=]:_2VJP%O+&BR W08?#=3BC+;CQ'1G]J#]JN"1I7Z"*H4!5
M 55%%4;  =AE:6\5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>'?F+9?5M:CNU%$OX%9
MC_EQ_ ?PXY((+SPMA5-- U+]%ZUIU\6XQPS*)B?]]O\ "_\ PI. J^H,BEV*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*OF7\\ORA_3T,_G'RS:UUNW3EJ^G1#>\C4?WB*!O*HZC]H
M?Y0WE$J^(\FAV*OHK\EOSB'E!O\ #?F:=V\M2EGL;NA=K*0[E:"I,;GL.C;]
MSD2%>:_F3Y]OOS!\QSZK/R@TZWK#HVGD[0P ]2!MS?[3'QVZ 80*5Y_A5E7D
MSREJ7G;S!8Z!IB\7N&Y75T02D$"_WDKT[ =!W-!WQ)I7Z8>6_+VF>5=$T_0=
M(A]&RT^,(E?M.QW>1SW9V))/CE24\Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O.
M?S+L_5T:WO56KV5P 6\$E'$_\,%PA7A1;_:R2J1; A]0^5M0_2?E_2[LMR<P
MB.8]^<7[MB?F5KD4I_BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?''Y[?E#]4:Z\\>6+7_ $5R
M9/,.F0K_ '3'K<QJH^R>KCL?BZ5I.)5\H9)#L5=BJK;P3W4\-K;1//<W,BQ6
M\$8+.[N>*JH&Y))H!BK]&/RB_+B'\O\ R\HND1_,6JA9=9N!0\.Z0(?Y8Z[T
MZM4]*963:7K.!78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%4C\RV?U_0-6MJ59K9
MWC'^7&.:_BHQ5\M%J9)"BSUPJ]P_*F_,NG:EIS-4V<ZS1C_)F%*#Y%/QR)2]
M7P*[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%5KHLBLCJ'1P5=&%00=B"#BKX/_.S\I'\H7<GF7R_
M;EO*]])_I%N@K]1F<GX:#I$Q^R>Q^$_LUG$VA\]Y)78J^O\ _G'O\L."Q>?M
M=M_WC@CRU:2#HIV:Z(/CN$^EOY3D9%+ZWR"NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5H@$$$5!V(.*OD/5+<V.HW]D1Q^J7$L-#_D,5_ADT):S^&*O0OROO
MS;>91;,U$U&WDB"G^9*2 _<I'TX"KZ-R*78J[%78J[%78JAY;RT@=8Y[J&&1
M_L1R.JL:FFP)WR$LD8FB0&482D+ )1&38NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*J%S<P6=M<7=U*L%M:QO-<3-LJ1H"S,?8 5RO-FAAA+),U&(
M))[@-R6>/'+)(1B+)- >9?'GFG_G('S'>7L\?E:.'2-,C)6WN)8EFN) -N;<
M^2+7J!QV\3GS_P!M_P#!5UV;*1H@,>,<B0)3/F;N(]U;=Y?5.S?8?38X ZDF
M<^H!J(\MMS[[^##O^5U_F;_U,W_3E9?]4,Y__DXW;W_*1_L,?_$.U_T(]E_Z
ME_LI_P#%._Y77^9O_4S?].5E_P!4,?\ DXW;W_*1_L,?_$+_ *$>R_\ 4O\
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MCT'\,U_:O:FG[,T\M1J)<,(_,GH .I/0?H<O1:++K,HQ8A<C]GF?(/DW7_\
MG(?S/>3R+Y?L;71[,$B)YE^L7!'8L6(0>- OTG/"^U/^"QK\TR-+"..'2QQS
M^/\ #\.'XE],T7L+I<<0<\C.7EZ8_K^WX,1;\[/S,9B1YC" FH06=G0>PK 3
MF@/_  1^WB?\8K_,Q_\ $.T'LAV6/\E_LI_\4M_Y77^9O_4S?].5E_U0P?\
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M7\YC)!K\4;.4/7N,V.#MC6X?HS3'^<:^5TX&;LC1YOKPP/\ FB_G5O8?+O\
MSEG^;NBLBZC?6'FBW4@&+4;5$?CW DM?0-?=N6;[2>W/:6'ZS&8_I#],>'[;
M=%JO8GL[-] E _T3^B5_93Z6\E?\YC>2=9:&T\XZ5=>4;IZ*;Z,F]LJ^+,BK
M*E?#TV [MWSL.SO;_2YJCJ(G&>_ZH_9N/D?>\EVA[":K#<L$AD'=],OU'YCW
M/K'2=7TK7;"WU31=1MM5TVZ7E;WUI*LT3CV="1MWSN,&?'G@)XY"43R(-AXK
M-@R8)F&2)C(<P113'+6IV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O.?S;DDB_+GS2
MT;%&-LB$C^5YHU8?2"1G(^W<S'L34D&O2!\Y '['?>S$1+M+"#WG[ 7Y[9\I
M/N3L5=BKL5=BKZ+_ .<>_-DMEK=SY3N92;+6$>XL(R=DNHEY-3PYQJ:_ZHSU
MO_@4]NRPZN6@F?1D!E'RG$6?]-$&_P"J'@_;GLP9, U41ZH;'^J?U'[R^Q,^
M@'RMV*NQ5V*NQ5V*NQ5\5_G[YLDU;S,GERWF)T[R\H$T8/PO=R#D[&G7@I"B
MO0\O'/G7_@I=NRU>O&D@?W>'GYY#N3_FBH^1XN]];]B>S!@TOCR'JR<OZHY?
M,[^>SP3/+GM78J[%78JF.D7$MIJVEW4)XS6UW!+$W@R2*P.WN,R]!EEBU..<
M><9Q(]X(+1JH#)AG$\C$CYA^GV?:#\[.Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\]_FW!Z6N6%
MR!07-D%8^+1NU?P89((>2LWCA5Z;Y"\AMKS)JVJJT>D1M^XB!XM<,IWH1N%!
MZGOT& E+Z U/5=-T33;K5]7OH=-TRPC,MY?7#A(XU&U69J=]O<[=<HSYX8('
M)D(C$<R>0;<.&>:8AC!,CR YOSM_-_\ YRQUG79;O0?RU>70M#!:*7S&1QOK
MI>A,(.\"'L?[SH:INN>4=O>W&7.3BT=QA_._BE[OYH_V7NY/J78?L5CP 9-7
MZI_S?X8^_P#G'_8^_F^-9IIKB62>XE>>>9B\TTC%G=F-2S,:DDGN<\_E(R-D
MV2][&(B* H!2P)=BKL5=BKL5=BKL5=BKTW\L?S5\T_E;KD.I:'>2/ILLJG6=
M!=B;:[B!'(,IJ%>GV7 J/<5!W'8W;>H[,RB>,^F_5'I(?K[CS'NV=1VOV+@[
M2Q&&0>JO3+K$_J[QR?LOIFH6NKZ;I^JV3F2RU.VBN[20BA:*9!(AI[AAGT#A
MRQRPC./*0!'N.[X+FQ2Q3E"7.)(/O&R.RQK=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M>;?F_P#^2W\T?\8(O^3\><?[??\ &'J?ZH_W47H/9;_C3P^\_P"Y+\^<^5'W
M!V*M]=AA5K KL53;0=7GT'6M+UJVWFTRZBN%6M.01@2A]F%0<S^R]?/0:K'J
M(<X2$O?1Y?$;.+K=+'58)X9<I CY]?AS?IA97EOJ%G:7]I)ZMK?0QW%M*/VH
MY5#*?I!S[&T^>&HQ1RP-QD!('O!%C['Y]RXI8IRA(48D@^\;%$Y<UNQ5V*NQ
M5V*I9K6JVVAZ1J6L79_T;3+:2YE%:$B-2W$>YZ#,/M'70T.FR:C)],(F1^ N
MOCR<C2::6IS0Q1YR('S?FAJ-_<ZIJ%]J=X_J76H3R7-R_B\K%V/WG/CC5ZJ>
MJS3S9#<IR,C[Y&R_0>##'!CCCC],0 /<-D%F.VM@$]!7O]V&K5K KL51=C_O
M;9_\9X_^)#+]-_>P_K#[VO-]$O<7ZB9]J/SF[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78JIR310J&FE2)2:!G8**^%3D)Y(P%R('O91B
M9; 6@!K6CLXC75K,N3Q"">.M?"G+,8=HZ4FAEA?]8?K;CI,P%\$OD4Q1TD4/
M&ZR(WV74@@_(C,N,A(6#8:""#1784.Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ53DEBA7G+(L25IR<A17YG(SG& N1 'FRC$R- 6E
MWZ=T0;'6+'_I(C_YJS#_ )3TG^JP_P!,/UM_Y//_ #)?(J\.J:9<GC;ZC;7#
M5 XQS(YJ>@V)ZY;CUN#(:ADB?<0?TL)Z?+#ZHD>\%'9DM+L5=BKL5=BKL5=B
MKQ+\Y8?W.@W('V7N(F/^L(V'_$3A"O.?)'EB3S3JZQ2AETRSI+J,HVJM?AC!
M\7(^ZIR1V5]1W=WIF@Z7<7MY-#IFDZ3;-+<3N0D4$$*U)/8!5&49<L,4#.9J
M(%DGH V8L4LLQ" N1- #J7Y/_GK^>6J?FGK$MAITT]CY'T^7_<7I9/$W#+7_
M $FX ZL?V5.R#;KR)\/]I?:3)VIEX8$C"#L._P#I2\^X=/?;[5[.>SN/LS'Q
M3 .8\SW?T8^7>>ONI\^YRST[L5=BKL59SH'Y9_F%YH1)M \F:QJ5M**QWL=I
M(+<BE=IF"Q_\-FRTO8^MU(O%BG(=]&OGR==J>U]'IC67+$'NL7\N;T"+_G&3
M\\9HUD3R,X5JT#ZAIR-L:;J]T"/I&;2/L=VJ1?@_[*'_ !3K#[7=E@UXW^QG
M_P 2A;S_ )QP_.NQ4M/Y#N7"J&/U>YL[@T)IL(9W)/ME>3V2[4ASPGX&)^XE
MGC]J^S)\LP^(D/O >;:YY,\W^6-_,7E?5=#2M!+?6<T"$G^5W4*?H.:C4]GZ
MG3?WN.4?>"/O=MIM?I]3_=9(R]Q!8SF(Y;L5=BK]J/R:D>7\I_RY:1N3#R]I
MZ _Y*0(JCZ  ,^A?9\D]G8+_ -3C]SX!V\ .T,]?SY?>]*S<.I=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BJ%N;ZRLQRO+R"T4@M6:18Q1>I^(CID)Y(
MP^H@>]G#'*?T@GW)?#YD\NW#^G!K^FSR$5$<=U"S4'L&.51UF"1H3B?B&V6D
MS1%F$A\"G((8!E(96%58;@@YD..WBKL5=BKL5=BKL5=BJA<W5K9QF:[N8K6$
M=99G5%Z$]6('09&<XP%R( \V4(2F:B+/DD_^*_*W_4RZ5_TF0?\ ->8_Y[3_
M .J1_P!,/UM_Y+/_ *G+Y']2;VUW:WD?JVES%=1&G[V%U==Q4;J2.F7PG&8N
M)!'DT3A*!J0(]Z(R;%V*NQ5V*NQ5V*O-OS?_ /);^:/^,$7_ "?CSC_;[_C#
MU/\ 5'^ZB]![+?\ &GA]Y_W)?GSGRH^X.Q5%V/\ O;9_\9X_^)#+]-_>P_K#
M[VO-]$O<66?F-Y>/ECSGKNE+'Z=J+@W%@*;>A/\ O(P/'B&X_,9O?:[LK^3.
MU,V "H\7%'^K+U1^5\/O#J^P==^<T6/(3O5'^M'8_/G\6$9S;N'8J^XOR&\Q
M_IGR6NF32<KORY,;5@35C!)62%C["K(/]7/I3_@8=K_G.R_!D?5A/#_FG>!^
M^(_JOCWMIH/R^M\0#TY!?^<-I?H/Q>VYZ.\@[%78J[%78J^>?^<AO,GU#R[8
M>7()*3Z[/ZMTH/\ Q[VQ#4/^M(5I\CGE'_!8[7\#10TD3ZLIL_U(;_;*OD7N
M?870>+J99R-H"A_6E^H7\P^-L^>WU=V*O2O*?EWZSY-_,#S/,A]+3;.&SLF(
MV,T\\32$'Q5 !_LL['L+LGQ.R]=K9#:$(PC_ %I2B9?*(K_.>?[3U_!K=-IQ
MSE(R/N$37S/^Y>:YQST#L51=C_O;9_\ &>/_ (D,OTW][#^L/O:\WT2]Q?J)
MGVH_.;L5=BKL5=BKL5?$_G?\[O-5_K-_;^6]1_1.B6\K0V9@1#+,J&GJM(RL
M1RZ@+2@H-SOGSE[2?\$CM#/JIPT>3P\,21&@.*0'\1D03OS %4*YG=]=[']D
M-)BPQEJ(\>0BS9-"^@ [O.]WG4OYA^>Y@0_F_5P":GA=RH?O5AG)3]K.UY\]
M5E^$Y#[B[Z/86@CRP0_TH/WH?_'7G?\ ZG'7/^XA<_\ 53*O]$W:O_*7F_Y6
M3_XIG_(VA_U#'_I(_J147YC>?(>'#S=JIX=.=S))]_,FOTY=#VN[8A5:K+MW
MR)^^VN78/9\N>"'^E ^Y[7^5/YQ>8+_S#9>7/--VFH6VJ$PV5^Z(DL4]"8U8
MH%#!S\.XK4C>F>C>P_\ P0-9J-;#2:V0G')M&1 $HRZ U5B7+<79&]/(^TOL
MKI\6GEJ--'A,=R+)!'7GRKGW5;ZPSW-\S=BKL5=BKL5=BKL50&IZKINBV<NH
M:M>PZ?90#]Y<SL$4> %>I/8#<YBZS6X-'B.7/,0@.9)H?V]PYEOT^FRZB8QX
MHF4CT#YQ\U?\Y%6T+R6OE#2Q>%=AJM^&2,^Z0*0Y'@69?]7/(NV_^"U"!,-!
MCXOZ<[ ^$!1/Q,?ZKWO9OL)*0$M5.OZ,>?QER^0/O>%ZQ^:'GW6V<W?F6[AC
M;_CWLV^JQT\*0\*CYUSS3M#VT[8UI/B:B8'=$\ _V-7\;>QTOL[V?IAZ<42>
M^7J/^RO[&#33S7$AEN)GGE;[4DC%F/?<FISF<F260\4R2>\FW<PA& J(H>2E
MD&2,L]0O]/D]:PO;BQE_W[;R-$WWH0<R-/JLVGEQ8IRB>^),3]C5EP8\HJ<1
M(>8!^]Z7H/YT>?M#9 ^K?IJV7[5MJ*^M7_GJ.,M?]EG8]F?\$3MC1$7E\6/=
MD'%_LMI_[)Y_6^R79^I&T. ]\=OL^G['TGY%_.CR]YNE@TV^0Z%K<Q"16LK!
MH9G.P$4M!N3T5@#V%<]@]F?^")HNUY##D'A9CR!-QD?Z,N_^B0#T%OG_ &S[
M):G0 Y(>O&.HYCWC](^-/9<]">4=BKR;\V_S"N/(6D67Z.ACFU?6))([)I@3
M'$D04R2%13D1S4 5[U[4/"^W?M7/L'30\$ Y<A(C?("-<4JZD6 !YWTH]-[,
M=A1[4S2\0D0@!=<R3R'V%\J/^</YD.S.?-$P+&I"PVX'T 14&>'R]O\ MPF_
MS)_TL/\ B7TH>RO9@%>"/G+]:W_E;_YD?]33/_R*@_ZIX/\ 1]VY_P I,OE'
M_B4_Z%NS?]1'SE^MW_*W_P R/^IIG_Y%0?\ 5/'_ $?=N?\ *3+Y1_XE?]"W
M9O\ J(^<OUN_Y6_^9'_4TS_\BH/^J>/^C[MS_E)E\H_\2O\ H6[-_P!1'SE^
MMW_*W_S(_P"IIG_Y%0?]4\?]'W;G_*3+Y1_XE?\ 0MV;_J(^<OUJT/YR_F5"
M25\S.]:5$EM:N-O]:(T^C+,?_!"[=@=M0?C&!^^+"7LIV9+_ "7VR'Z62Z?_
M ,Y!^>K1E^N1:=JD?[?JP&-Z>QB= #\U.;C2?\%7M?$?W@QY!YQH_P"Q('V%
MU^?V'T$_H,XGR-_>#][U?RY_SD-Y;U!X[?S!I\^@S/L;I#]9MZ]*DJ%=?^!/
MSSN>R/\ @KZ'4$1U4)8CWCUP^P"0_P!*?>\UK_874X@98)#(.[Z9?J^T/>;&
M_L=3M8;[3KN&^L[@<H;J!Q(C#V921GI^FU6+4XQEPR$X'D0;!^(>+S8,F&9A
MDB8R',$447E[4[%78J[%78JE^J:MINB64NHZM?0Z?90#]Y<3L%6O8"O4GL!N
M>V8NMUV#18CESS$(#F2:_M/<!N>C?IM-EU,QCQ1,I'H'SGYI_P"<BK6!Y;;R
MCI?UTKLNJ7_)(B?%(5(<CW9E^6>1]M_\%K' F&@Q\7].=B/P@*D?B8^Y[SLW
MV$G("6JGP_T8[GXRY?('WO#=8_-/S]K;.;GS)=6T3$TM[)OJJ ?R_N>)(_UB
M<\U[0]MNV-:3QZB41W0] ]WIHGXDO8Z7V;[/TP].*)/?+U'_ &5_8P2>XN+I
MS+<SR7$AZR2L7;[V).<QES3RFYR)/>3;N88XP%1  \E'*V;L53G3_,6OZ25.
MF:W?Z?PIQ%O<21C;M16 I[9L=+VMK-)7@YIPK^;(C[BXF?0:?/\ WF.,O> 7
MJ&A?GQYZTED2_GM]?MAL8[N,)(!_DRQ<#7W8-G:=F?\ !.[7TA RF.:/](4?
MA*-?[+B>=UOL7H,^\ <9_HG;Y&_LI]%>3?SF\I^;'ALYY#H.KRD*MA=L/3=C
MVBGV5O  A2>PSUKV>_X(79W:I&.1\+*?X9'8G^C/D?<>$GH'A.U?9/5Z$&8'
MB0'6/,>^/,?"QYO7,[QY=V*NQ5V*O)OS@MWF\O:<\2&21=2C1545)]2.0;#K
MU PQ5E_DWRZGEK0K6P('UN0>MJ$@_:F<"HKX***/EB2KX=_YRY_-N2\OQ^5V
MA79%C8%)_-LL3;2W&SQ6I(ZB,4=A_-0=4SRGV[[=,Y_DL1V&\_,](_#F?/W/
MJ'L1V((0_.9!N=H>0ZR^/(>7O?#.>;OHKL5=BKV3\I_R2\W?FQ>DZ9&-,\O6
MLGIZEYDN5/HQG8F.)10RR4->(V&W)EJ,W_8?L[J>U9>CTXQSD>7N'>?+YD.A
M[;]H=/V7'U^J9Y1'/WGN'G\@7Z0_E]_SC]^6WY?0P26NBQZYK48!DU[5%6XF
MY>,2,/3B]N"U\6.>M]E>RVAT !C#BG_.EN?@.0^&_F^4]I^T^MUY(E/AA_-C
ML/CU/Q^3VW.C>>=BKL5621QS(\4J++%("LD;@,K ]00=C@(!%%()!L/%?.'_
M #CQ^4_G)97NO+$.BW\E::GHU+*4,>K%$'I.3W+H3G.Z_P!E.SM9SQB,N^'I
M/R&Q^(+T&A]J.T-)RR&0[I>H?;N/@7QE^8G_ #B-YT\M+/J'DVY7SGI25;ZD
MJB'48UZT](DK+3_(/(]DSS_M;V$U6FN>G/B1[N4_ER/PW\GO>R_;C3:BHZ@>
M'+OYQ^?,?';S?)L\$]K/-;7,,EM<V[M'/;RJ4='4T965J$$'8@YPTHF)(D*(
M>UC(2 (-@OVS_+'2YM$_+GR+I5RI2ZL=!T^*Z1NJRBW0R+T'1B1GT5V-A.'1
M88'F(1OWT+?GWM?,,VMS3'(SE7NLTSG-DZYV*O@C_G(7_G)#S7Y=\VWWDCR'
M=QZ0FBA$UC6O2CFGDN'0.T47JJZ(J!@">/+E6A &_F/M5[6ZC3Z@Z;2GAX?J
ME0))YT+L #W7;Z5[+^RFGU&G&HU(XN+Z8V0*[S6Y)]]4^<?^AC?SJ_ZGRZ_Z
M1[3_ *HYR7^BWM3_ %8_*/ZGJO\ 0KV9_J(^<OUN_P"AC?SJ_P"I\NO^D>T_
MZHX_Z+>U/]6/RC^I?]"O9G^HCYR_6[_H8W\ZO^I\NO\ I'M/^J./^BWM3_5C
M\H_J7_0KV9_J(^<OUN_Z&-_.K_J?+K_I'M/^J./^BWM3_5C\H_J7_0KV9_J(
M^<OUN_Z&-_.K_J?+K_I'M/\ JCC_ *+>U/\ 5C\H_J7_ $*]F?ZB/G+];O\
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M.7]:<HG?W1J/P?+,>O\ SGM#&8/I$C$>Z,2/M-GXOC[/ 'U-V*HNQ_WML_\
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MSZJDA]+<@;(+AZGV%8P,!_X%7; '/&?\X_\ $J/;CL\_S_D/UL \R?E]YO\
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MD1^GO-GJ^[=E=F8NS\$<./IS/61ZD_C8;,7S2NQ=BJY59F554LS$!5 J23T
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M_P",S/\ U7>>S7_&EA_K/QJSP!]Y=BKZK_YP[_\ )M7/_; O/^3MOG;>P/\
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M?Q=?3SX#VJ]IY:<G3:8U/^*7\WRCY]YZ=-^7KJ...&-(HD6**-0L<: *J@;
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M]-*L8V,ASEWT?YOW^Y]EYZ \$[%78J\Y\_\ Y4>1OS*LVMO,^BQ3780K:ZU
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M5OR8T#]/>?=*9TY6NC<M2N?G 1Z7_)5DSN/^!YV7^?[8Q$CTXOWA_P WZ?\
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M]YWE]I+%LTCLG8J]K_(GRPFO><1J-U'ZEEY<B%V0153<,>, /R-7'NN>C?\
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MRY_ OU)SVA\=>1?GW_Y)W\P?^V4__$US0^T__&9G_JN\]FO^-+#_ %GXU9X
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M_)^/./\ ;[_C#U/]4?[J+T'LM_QIX?>?]R7Y\Y\J/N#L51=C_O;9_P#&>/\
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M@\C$_<VZ<D9(D=X^]^7N?%C]%NQ5V*OKW_G&W_CB>9?^8Z'_ )-9[W_P(/\
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M]1_^<.__ "4MS_VW[S_DU;Y[/[ _\9Q_KR^X/COMW_QH#^H/O*M_SEA^7O\
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M\GX\X_V^_P",/4_U1_NHO0>RW_&GA]Y_W)?GSGRH^X.Q5%V/^]MG_P 9X_\
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M?GSGRH^X.Q5%V/\ O;9_\9X_^)#+]-_>P_K#[VO-]$O<7ZB9]J/SF[%78J\
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MWE"\N)!'::C<-I5VQ-!2^0PQDGL!*R$U\,Z'V4U@TO:6*1Y$\)_SMA]M//\
MM3I#J>SLL1S XA_F[G[+?L-GOCX4[%78J[%78J[%7@?_ #D__P"2,\\?]NS_
M +J=IG,>V7_&3F_S?]W%Z7V/_P"-7#_G?[B3\B<\)?<'8J[%7[:?E3_Y*[\M
MO_ 6T?\ Z@H<^B>Q/\0T_P#PJ'^Y#\^]M?X_G_X9/_=%GV;1UCL5?C7^??\
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MLD\HZ)%YD\RZ/H4\[VT6IW ADG0 LH()J =NV;?L'LV/:6OQ::4C$3E5CF'
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M/]27WAXSV[_XSQ_7'W%^H^>SOCKL5>)?\Y&_^24\^?\ ,+;_ /47!G.^UO\
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M'TO_ ('?_(C_ #/]^^!L\Q?2G8J_4?\ YP[_ /)2W/\ VW[S_DU;Y[/[ _\
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M$1$>Z(I^?-1GEGRRR2YR))^)M'9DM+L5>;?F_P#^2W\T?\8(O^3\><?[??\
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M?.&<D]6[%78J^_OR _YR<L8K&Q\E?F7?_5)+14M]$\US']TT2CBD5X_[+**
M2'8C[9!')O4/9?VQ@(#3ZR55M&9Y5W2_XKY]Y\S]IO9"9F=1I(W>\H#G??'_
M (GY=P]W6]Q;W<$5U:SQW-M<()(+B)@Z.C"H964D$$=QGI<)B8$HFP>H?.)1
M,21(40K9)B[%6!>=_P S?(_Y=VC7/FK7[>PE*<[?3%;U;R;K3T[=*N02*<B
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M4R_YO^XB]4SMWFWR;_SDK_O=Y2_XP7G_ !*+/"_^##_>Z7^K/[XOIO\ P/\
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MQV*OQK_/O_R<7Y@_]M5_^(+GS_[3_P#&GG_K/O/LU_QFX?ZKR'-$[QV*L_\
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MO3D_N.(=\91/V7Q?,/KF#VL[-RC^\X3W$$?HK[4L_P"56?F%_P!2I??\"O\
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MP0Y>BU^?1S\3#(Q/EU]XY'XOF_S+_P XYR!I+CRGK*LIJ5TW4=B.]%GC!KX
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M/^QM[%Y<_P"<<KJ1HYO-6M);Q=6L-.'.0^QFD4*I^2M\\] [(_X$>21$M=F
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MU'_90_XI?]&'97^K?[&?_$N_Z%@_//\ ZD?_ +F>F?\ 97C_ *#>UO\ 4?\
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M%C+]&($=21MO05I7/6O9;LK+V;HABRUQ&1EMTNMK^#Y3[3]J8NT=8<N*^$1
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M&AJKR@_Z1*/]9QQ![A0<LB$/%L*NQ56M[>:[N(+6VB:>XN9%BMX4%6=W(55
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M[%78J[%78J[%78J[%7YW_FG_ .3"\U_\QS?\17/DWVV_XVM3_7/W!]U]F_\
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M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_._\T__ "87FO\
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ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\[_ ,T__)A>:_\
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MWE(J].OP*0?YADA%7R?YQ_-#SEYX9H]9U1H]/)JFCVE8;4;U%4!)>G8N6.2
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8BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140700852368816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MV0_@_4HI\]&PA];B?P[]_P!02P,$%     @ RH"I6)^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( ,J
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,J J5C&BX,@2 0  '\0   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #*@*E8GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ,J J5B7BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,J J5BJQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #*@*E8)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #*@*E899!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mgnx-20240509.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="mgnx-20240509.htm">mgnx-20240509.htm</File>
    <File>mgnx-20240509.xsd</File>
    <File>mgnx-20240509_lab.xml</File>
    <File>mgnx-20240509_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mgnx-20240509.htm": {
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20240509",
   "dts": {
    "inline": {
     "local": [
      "mgnx-20240509.htm"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20240509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20240509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20240509_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://macrogenics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20240509.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20240509.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001125345-24-000091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-24-000091-xbrl.zip
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M1W*+)4'%%&>&\E8$62E.1>&G8XIM4]U0!Q2 ,ARF;&?=[H)2I;:%"O!%4M^
MEPCO$ UFZHVN@=_/C]9K2?&;]Y\*KNYN_JL\4UDO,?^UT%_80?K#D%Y4D%=#
M=-:7F2L/?H.((PZ8A_[QQ4G%!J^U;K>.V/'UIUZER4YZE]?OWMH'S:.\2/:4
MXX&(ADB93<CD[NILU#OG5D_\=CQ* BZCT]17M\(J8CNB]"37\^G+Y=EOIZ?7
MZ#$ML!JK?]Q5CHCYO?#8+3A2D[^XAPX\O&&2?Q4DH#55-[D2<*!0HWL$?J")
MI3-W'+WX?++3;M4F?CKF.#''E=93!B\LJQ.=3<31Q*!='!.-Q9C1+&]O;*&I
MS)RF07$*)<^!FN&OGPEE>YC\WG\PV8#3;\B!^0K=>0(?,P5IR6"<,3*IB4FH
M0U5BLP$/9*3C8FJUM4:.X=7-')UZDH7(%S)<</3YSA-^]AQ)Y_4 LQ@>(L]Q
M1CH*J?(E2CE$GB>]S]U"[B1WC5$?(I'&KKHXKU $.6PS@]<TYY)_ ?0O2Y'D
M\ZN!HI+-Q:0,%906D5D0L"P#DP:6SAAP2MTC)IA0L6H&@"D85VJ<GQE&,J"V
M?$!&SU.@TS$=*0[XQ.%6=]]DCWR1K92B2!Q:88;\>(GBRD$2.&EF,1Z'F.(
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MSRR23??ZIE@_(X9V$W?0?:48@J?XF U;:L)DL-"$%3809D_@C*)R;K(9 .@
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M/"P]6?JA8Z5+1*>]). 0$,7"W7]>,7F<,%.-/%878,[#@D!$@(?UI,.[7X;
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M)5 QZPL<4F8AK+2;QAM#[53?K+?H:@(\<4"9,,:HARQ,*&)I7.-(2+^?1-K
M$XZD:)5(3/#(].Y1AJ30.F=)F-H1@BC#^UG,6CHRTYQ*HB+$HBV2KEAFB^ )
M? 'T!MP[$:5=0L%-,))#V"/9E0'JH+'8>'>Y20<Q2T<T8Z@G3?-;#CJ<]A&?
MAZ@*K+1AX"!)[08"713,^R#8WWG3:UJ?,FOP+/QMLH'@-PX5_ES8J:D.D=W*
M70]BBSF1XJ$6ICZ<A\:F%8*M6(0HJ'\F$J.5E(H%D0#IE^(.!X9F:TFC11$B
M+V/Q]R<LF#>J$RX "' #1+G@WHJ,LGJA,!4BS4GE*".@DX@SY%$,H:LNV%)
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M^=Y\]]G!;\L.S#F_>]MN'LWDD<O/F)]P3@)^C&+?>_]_4$L#!!0    ( ,J
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MZ=@)PH ! GSD8$<FDI_<\U@@?T+[!2B0X&XR_BANLLY)P56 :0'M(23&G7H
MPXUK@)V@?B/PV.@S&Q<(]TX*'<70"U4-B*P;MFG9Q\4YJ&L,<@IZ[*$N?_+I
M38$D@G12 .%S.GS$/*5#?12.=%2C4/UT^J557QBP.#]#P3I,@ EAT1+&H,@Y
MD90,0(E(U7%B8,=)(>*]OH]LE^^Z C&>XX$ZBCS@D!QO.D@Z9A0.A'R2\N6D
MTY:XX[2S]TP2-GOB'CYW.!-$XL26:ERM\7F>X/<_KF:OYJ'W@3RAESV!5(OX
M(YC,*LY'T4!5*]EWT[8)FMZ*KEE+]IP-4IR;=T:D"56*,P)9!+%-9!>IPQ^S
MF'\A]:;?I/+>XX'296C6'<ONQT=#[L5=1]>T?Q1DO^IQU*<@$&V!'$M^)T 6
M0"'""O7Y3>"X0$$F"LG'6;L;^J%P?M7DWU$'9@B2V>/^V/EPS7L@9A=L2)IA
MCP8?#B*PB& Z!>\D'2/^/^;H%B H'X<)QB6 @]8LFX%N(-I?+QK7]8^D=7UZ
M76_-X[R#V+;JM:_-QG6CWB*G%Q])_5OM]].+LSJI79Z?-UJMQN7%PA16\^15
MYZ?EFA_Y\[3U>^/B[/KRXH!\5&LJA ^V5=DAO*VE>/^UY&]MI+?.HW(N'GVZ
M;)Z3_ XGBQT3]YNX%3 N9>7SHD_9\9G_\U?]4#O:(6%<CB:8B&;]XIHTZU>7
MS>LW;A"N!B(:4$@]XI"TF(LQ+]%-$@JBVWO>/@D[F(?L_#P ]8'@,0>(]9';
MA?"(D5,W1O3UBFGM//X[)_K+[3!&24A3P?JAB,E>]LPHQ$DLB@F[PS0V:6;>
MOI/,ZPGF[$J&8/4D,)N/HSUXH_0 1!<_4SPZ5L: @,*"25A=J)[3<3)VY4"F
MR#MD#/.1>NL2<9A+<-=-OYKLAD>88\<7T)(QS 2&G=::EV?UBT:M=4 :%S5U
M%SDF(3H\AM'<'#PD>_41!2N$4T4UF4Z>T(BT^LS%5,<C/""U+F0K3.SOPBS7
MD,N8MGV6H= .!>1""F#BTW[$G.S'49;')^4.17YTU*/B!O*==AC'8<_!=.>.
MB9B[U$^G*6><-*>94*6BVH<Z2ET,*5?L90.G>9(*^!47WYNF6K;*2YLT55_Z
M?A4HHZ)JFK$14(B5O;PI U64LTQF"K1$BI\4S$+6N4\]+"@Z1G]$="#?C(3X
MK+-(SK!?V#7?ISW%A#0"-Q3@8&2!KA6#-ZB%@R 6XUKHS;L*K/=A'2!F?1'>
M(9RIC[# FS&?#JE@#UN:8NS]Y, \!SYQGT'G-B"<4M/&8HZNF(>Z;OPDYYKD
MO*:C1EKW<J50S]/V$&A[J.AV13_4S1S$W:S92 SPU@B=W^-*TN])>X#IRR6D
M+8+\ 5E!Y'&9U^R":UUS.A SS%F[_9?2I3?&Y5K8Z_$H>IM,32(HM*$D4?2?
M7$VXVFBV2+W7]\,Q$V^6K_.6G%R$ZC+V2AM=E(%PWM+1:P?;Y9)J&8?K!MN&
MJ5KEY9'PVL&VK1[:]D9 Z9I:*FTH;@>L*@^#6NJ #S>IQ"D(!?L[AJ66D*/9
M2[DO8/+VK09%IYXG6!2E_WP!>'H6$)4*U4I)L\@Y\Y!.I";G13X*?O?\6%Y#
MGJ3<S=/MZ=&6Y--*;K\A'M7@YZ6X#H>3Y*I<J#9#]_:.^SX[6,F2S?NY-T0T
M&:A>BBM(3+G<F9$S;ZU@;5.,?1IXSR!L3BE?0O_$B"S/Q=X0^:]"H*__']Y/
MB@;INIE6J!I:V=8>I.S3S?OV:+<BXDJ)@;7)*P%BR/M@3NLCY@YBL*7DL@-Q
M#(OVW[E@K2 ." =!Z=A?Y/YZD=NNE7"G9>@/$8F9S_K=,& DD,G( 0$Y\ ?(
M)4(%H\!%CTW6<=*I;6.);"^_IJ-#.@7<YW1;+U1-3;^OV?MKK$U]"4$NKY!6
M\P4:W0"S8>N*K9<>*7[MH#!L?9TI'_<OPIC0?A\R,=2\W4%ZS16AO4_@Y2%6
M35:$!$D?4SL,NM?!E:#@AGFDA6$!^4*CF#3E>NKZ:T,K,\E98K2I>WLCPD'@
M*2E=.O+OZ!4D4+?GU^Z%M$Q,P/3[RS8F&'OM;$L"+N\[6UN&*FFEM9>A+%6K
M/+S@DSLSME3;KFPFG2VKFOUPOI[&.UECRCL3W/R\EZ\\FB0]"N+YZ=AFLK:5
M.I'*ELR[ 12)0I][)-.1M!5BEB6-&UG=X &6EX";NJ3=-@+N:]RSG6SZ<+O$
M]6D4Y4ZR7YFNNY:K7 LJXZK6N-<._;U<@?7S2);4@GY02<VV74A!9=FV,/ C
MPRZ'-U-GL_XBVF-<2=W)2L+_& 9D>6*5/^!.(X.Q;K2EU9D$W&:ABDM P,I6
M'+JW!Z1/!;FC_H"1OVNJII,^GC[H/F=M?\<XO&O9<7XFID8OL7D3#EJ%ZOG9
MQ;<GE+!>EC$_B,'<E&9FFVV3S7SW2YAH<^>KE[J-9CGRZ'=RYH=MZD-L[T-T
M3\ZIN&5QWMT-"_67MYA5IPPW#R?\SE,_6OSJM>=6ZS+W5J9@D)"+L"\X;KEH
MAR/29GXXQ!P6&S&U)67E,^EP'X,>'A&.9P,]2.X@IXMX;^#'-&#A(/+')*(Q
MCSIC^67Z0=@&/B:KJ&G*)Z;[)T']P<338)RU=2#+"X?X'=;,.>X-B,A>Q!@Y
M8P$3(&F- +X=))GDJ6JH";K[SDIZIZDAZKR1:?7VR9]?2?\$#06"HZ<<!.F"
M=+2HI>TP]$$3_3 &'DX4]1"%N%*RK*/[2DE2N##T+."YC+TYR(HTEF&GS$(N
MS>3ZN#U_3R^1VJ<F,4Q-A8ZK*QQOG14M\!<NS#NX.0=E 8WQ\_*AM)H/4Z"D
MET)=P03=HHINS/!A[I#$A L6I/RRY_MEQ)5@J ]XRE6>FD)[)"X[':SFYF-(
M>35# +CBSD#/IR&ZY2FRL)6+/4G?'X9!C2@:,/$$-E4VSB:3*=:>FX]-:=]%
M-N5R](LUR1FNVO>XBH?KML351H ;,-#YCXDKHP+ \Q;2:R8W7]YSV1   (I
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MG)J=[CXN1 !9T9VW&02Y0""/%#K<9YZ,G-#A@H]CDFD3AUO.':Y*,9EM*LC
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M EXYY4[GQ?85)/AYS$T/L3LR2,1>@!-=6NY@"5&.MHX@2:Y,3?&I5!2=41$
M\2,9F@JF=F,@+<;YQT7Z8E==_&3AB[/P2F:ZS333]62B<RYY^C[F1\>D\HZF
MD]WJME3GWJ0K7+XE2]>LY^R)>TM3K86 #;FB-XPT,,H#L<1#B!]I3,D>@TC
M\]*K\2'=Q[I!0T9U1%ZA[Z7W!C[[L-X32HGF_+*4N1NG[I-[,1MG%Z?77YOU
M9TYE[;UJ3P7[VA6^V?M/D[6X[P,NTCPY7P7N8-DBGC?PQ\2E UQXDV7"],I,
M&*8->0L(!C1 ! AY$[SH4K^#I2T$)$UAVJ'+!!L$\(T$1P=Q-Q0P.6^QOO76
MZ+[5:P3+JF'9ZV9S5ED]W-#=?Y9JV*7-0,*[#7,=WWK7K@,OB75P585,KGM=
MX3.?? W+J]7QEL]PR?6H3PU[GGY$?P?I\MO8V6K2]8*3>RCI*D9%\@?K= 0;
MDRL&\46T_14SR8^=1*K% AX*\F_N,MS\%\G_9416P;.]X7B#:,3\3=W4E2-
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M& ;>^3$X8QJH7\K'@ &WG8M?=Z]/P>T!V\.Q3R*$-(YO)3M9TW!1R*V@%]G
MLR'Z%13#JKR8_U=&Q+TRHOK)J]Z8IZ!1L@%E..C#W7$&U@J*N6<W" ]3^Z-1
MX/>1#) 7#HY;8-6]!]#]XKA\E_N$!A/FJ>E-Z+X/%6Q+]#_G7Y'\W/Q["E1G
M)FZ)M[T><3;WKF1_^WO(RNY6'T_>+,[9%CL8&\PQ*+C@;N!"]T0([_\3&#G6
M1? <^\Q*JX%]$0MW?M[4'7D'^0.1DHJVU?F\?5@G:3OA4+O=;@7'R[7]/EA
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M0%(90!*%,812Q-CG?A('QL??+X./ U>M9_VECZTZF!+EYLX))A-C#AAM.QA
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M[D]T']W+\$=[?P-02P$"% ,4    " #*@*E8F5!;SM<K  #"?@$ '@
M        @ $     97AH:6)I=#DY+3%E87)N:6YG<W!R97-S<F4N:'1M4$L!
M A0#%     @ RH"I6-/,!W^0#P  N&H  !$              ( !$RP  &UG
M;G@M,C R-# U,#DN:'1M4$L! A0#%     @ RH"I6.6WMP]M @  ;0<  !$
M             ( !TCL  &UG;G@M,C R-# U,#DN>'-D4$L! A0#%     @
MRH"I6#RCI6C_"0  ?50  !4              ( !;CX  &UG;G@M,C R-# U
M,#E?;&%B+GAM;%!+ 0(4 Q0    ( ,J J5@KN+'GK 8  -PP   5
M      "  :!(  !M9VYX+3(P,C0P-3 Y7W!R92YX;6Q02P4&      4 !0!0
) 0  ?T\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>mgnx-20240509_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20240509.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001125345</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36112</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Rockville,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
